Center-Specific Survival Analysis
Outcomes reporting in allogeneic HCT is necessary to provide information requested by patients, insurers, and government agencies and to comply with current laws. The SCTOD contract requires CIBMTR to conduct an analysis of one-year survival rates at each transplant center in the US annually. The report generated by CIBMTR is meant to be useful as a quality improvement tool for participating centers.
Additional information about this analysis and data are available.